TechnoVax Inc. Awarded National Institutes of Health (NIH) Grant to Develop a Universal Flu Vaccine Based on Its Virus-Like-Particle (VLP) Technology

Published: Aug 01, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TARRYTOWN, N.Y.--(BUSINESS WIRE)--TechnoVax, Inc., a biotechnology developer of novel vaccines has received a two-year $600,000 SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant is to support TechnoVax program for the development of a universal influenza vaccine utilizing its proprietary VLP technology. “We greatly appreciate this NIAID grant and this funding will accelerate the development of this much needed vaccine,” stated Dr. Jose Galarza, CEO of TechnoVax. “This award recognizes not only the innovative research carried-out at TechnoVax but also emphasizes the importance of developing a flu vaccine that can protect against multiple virus strains, including pandemic ones, and whose protective effect could last for several years: effectively bringing us closer to the development of a truly “universal” flu vaccine."

Help employers find you! Check out all the jobs and post your resume.

Back to news